

LIQUID BIOPSIES
cancertrack[®]
NON-INVASIVE INTELLIGENT MULTI-COORDINATE



**THERAPY
GUIDANCE**

Blood-based
liquid biopsies for
all solid organ tumors



DATAR
CANCER GENETICS
UNITED KINGDOM | GERMANY | INDIA



About Cancertrack™

Cancertrack™ is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. Cancertrack™ can be used to monitor the disease / recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, anaesthesia or painful surgical biopsies.




Features of Cancertrack™

- ▶ Multi-coordinate and multi-dimensional probes to track down DNA and RNA released by cancer cells in the patient's blood
- ▶ Unique, unprecedented capability to detect cancerous activity
- ▶ Enables real-time, rapid response to the dynamic molecular profile of a patient's cancer
- ▶ Safe, accurate, simple, and cost-effective
- ▶ Non-invasive blood test
- ▶ Not dependent on the availability of tissue
- ▶ Tests all active disease sites
- ▶ Limit of detection is 0.1% Mutant Allele Frequency
- ▶ Far more powerful than conventional biopsy
- ▶ Extensive coverage of NCCN recommended biomarkers



Keeping track of cancer is very critical

Cancer is best managed by a treatment plan that stays one step ahead of the tumor. However, conventional techniques such as imaging or scans can take more than 3 months to detect whether or not the treatment is working or it has failed. That is why, it is important to determine as quickly as possible, if the cancer is responding to the therapy or is progressing. This information is now available through Cancertrack™.



Suitable for



Every person who has been diagnosed with cancer; as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumor DNA and RNA before the initiation of therapy

Every patient who is in remission or a cancer survivor and needs monitoring

Every patient who is under treatment for cancer

Every patient in whom the cancer is not responding satisfactorily to 'Standard of Care' therapy



Analytes



ctTNA: Circulating Tumor Total Nucleic Acids

Indels: Insertions and Deletions

mRNA: Messenger RNA

SNV: Single Nucleotide Variations (Point Mutations)

NCCN: National Comprehensive Cancer Network

FAQs



How is Cancertrack™ validated?

Cancertrack™ has been validated clinically on several hundred samples and the process validation meets and exceeds the claimed sensitivity and specificity. Our laboratory is accredited by ISO 9001:2015, ISO 15189: 2012, ISO 27001:2013 and CLIA besides its compliance to "The College of American Pathologists" guidelines. All Cancertrack™ reports are reviewed by our experienced and qualified Molecular Tumor Board, comprising of experts in the field. Our counsellors and experts are available for ongoing support.



Why is early detection of molecular dynamics of cancer critical?

The rapid and continuous evolution of the molecular profile of tumors results in tumor heterogeneity, which confers significant survival benefits on the tumor. Cancertrack™ unravels these molecular features in real-time to identify critical signs linked to recurrence or emerging drug resistance and novel vulnerabilities, which empowers the treating clinician to avail optimum treatment strategies to intercept such cancers in a timely manner.



How frequently is it necessary to do the test?


Cancertrack™ should ideally be performed at every important milestone in the fight against cancer and especially when the tumor has disappeared from the conventional imaging/patient is under follow-up for recurrence monitoring.



What are the limitations of Cancertrack™?

While Cancertrack™ is extremely robust and multi-dimensional, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.

Sample Requirement : Peripheral blood as per DCG protocol.





DATAR
CANCER GENETICS
UNITED KINGDOM | GERMANY | INDIA

Accreditations for Our Lab in India



Advena Ltd. Tower Business Centre, 2nd Fl.,
Tower Street, Swatar, BKR 4013, Malta

Contact us:

✉ enquiry@lifeomicsdx.com 🌐 datarpgx.com

Proprietary Technology, All Intellectual Property Rights Protected under relevant laws.